WO2006103298A3 - Blood coagulation fviii analogues - Google Patents

Blood coagulation fviii analogues Download PDF

Info

Publication number
WO2006103298A3
WO2006103298A3 PCT/EP2006/061275 EP2006061275W WO2006103298A3 WO 2006103298 A3 WO2006103298 A3 WO 2006103298A3 EP 2006061275 W EP2006061275 W EP 2006061275W WO 2006103298 A3 WO2006103298 A3 WO 2006103298A3
Authority
WO
WIPO (PCT)
Prior art keywords
fviii
introduction
injection
analogue
clearance
Prior art date
Application number
PCT/EP2006/061275
Other languages
French (fr)
Other versions
WO2006103298A2 (en
Inventor
Henrik Oestergaard
Gert Bolt
Steenstrup Thomas Dock
Original Assignee
Novo Nordisk As
Henrik Oestergaard
Gert Bolt
Steenstrup Thomas Dock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Henrik Oestergaard, Gert Bolt, Steenstrup Thomas Dock filed Critical Novo Nordisk As
Priority to US11/910,349 priority Critical patent/US20080227691A1/en
Priority to JP2008503532A priority patent/JP2008534559A/en
Priority to EP06743235A priority patent/EP1871801A2/en
Publication of WO2006103298A2 publication Critical patent/WO2006103298A2/en
Publication of WO2006103298A3 publication Critical patent/WO2006103298A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.
PCT/EP2006/061275 2005-04-01 2006-04-03 Blood coagulation fviii analogues WO2006103298A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/910,349 US20080227691A1 (en) 2005-04-01 2006-04-03 Blood Coagulation FVIII Analogues
JP2008503532A JP2008534559A (en) 2005-04-01 2006-04-03 Blood coagulation FVIII analogue
EP06743235A EP1871801A2 (en) 2005-04-01 2006-04-03 Blood coagulation fviii analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500462 2005-04-01
DKPA200500462 2005-04-01

Publications (2)

Publication Number Publication Date
WO2006103298A2 WO2006103298A2 (en) 2006-10-05
WO2006103298A3 true WO2006103298A3 (en) 2007-04-12

Family

ID=36600697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/061275 WO2006103298A2 (en) 2005-04-01 2006-04-03 Blood coagulation fviii analogues

Country Status (4)

Country Link
US (1) US20080227691A1 (en)
EP (1) EP1871801A2 (en)
JP (1) JP2008534559A (en)
WO (1) WO2006103298A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RU2008145084A (en) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
CN101516388B (en) 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
FR2913020B1 (en) * 2007-02-23 2012-11-23 Biomethodes NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
DK2144923T3 (en) 2007-04-03 2013-05-13 Biogenerix Ag METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
CN101965200B (en) * 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules
EP2337580B1 (en) * 2008-09-03 2012-03-28 Octapharma AG Stabilized compositions for recombinantly produced factor viii
US20120027743A1 (en) * 2008-11-03 2012-02-02 Bayer Healthcare Llc Method for the Treatment of Hemophilia
CN102348715B (en) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 Extension recombinant polypeptide and the composition for including the extension recombinant polypeptide
US20120093840A1 (en) * 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011101242A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
JP2013532176A (en) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス Stabilized factor VIII variant
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
DK3626737T3 (en) * 2011-05-13 2024-02-05 Octapharma Ag METHOD FOR INCREASING THE PRODUCTIVITY OF EUKARYOTIC CELLS IN THE PRODUCTION OF RECOMBINANT FVIII
JP6352806B2 (en) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス New glucagon analogues
WO2013066986A1 (en) * 2011-10-31 2013-05-10 Puget Sound Blood Genter Antibody response phenotyping
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013122617A1 (en) 2012-02-15 2013-08-22 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
JP6523244B2 (en) * 2013-03-15 2019-05-29 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Mutant factor VIII polypeptides and methods of making and using them
RU2683039C2 (en) 2013-04-18 2019-03-26 Ново Нордиск А/С Stable protracted glp-1/glucagon receptor co-antagonists for medical use
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
CN106536547A (en) 2014-06-04 2017-03-22 诺和诺德股份有限公司 GLP-1/glucagon receptor co-agonists for medical use
EP3191524A4 (en) * 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
WO2016127057A1 (en) * 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
CN108472337B (en) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 Factor IX fusion proteins and methods of making and using same
JP7235511B2 (en) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Recombinant single-chain FVIII and chemical conjugates thereof
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071714A2 (en) * 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
EP2572732A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
WO2000071714A2 (en) * 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANANYEVA N M ET AL: "Catabolism of the coagulation Factor VIII: Can we prolong lifetime of fVIII in circulation?", TRENDS IN CARDIOVASCULAR MEDICINE 2001 UNITED STATES, vol. 11, no. 6, 2001, pages 251 - 257, XP002320945, ISSN: 1050-1738 *
SAENKO E L ET AL: "Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 274, no. 53, 31 December 1999 (1999-12-31), pages 37685 - 37692, XP002152276, ISSN: 0021-9258 *
STOILOVA-MCPHIE S ET AL: "3-Dimensional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography", BLOOD 15 FEB 2002 UNITED STATES, vol. 99, no. 4, 15 February 2002 (2002-02-15), pages 1215 - 1223, XP002388006, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1871801A2 (en) 2008-01-02
WO2006103298A2 (en) 2006-10-05
JP2008534559A (en) 2008-08-28
US20080227691A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2006103298A3 (en) Blood coagulation fviii analogues
WO2007135182A3 (en) Factor ix analogues having prolonged in vivo half life
MX2009003737A (en) Injectable depot composition and it's process of preparation.
LTPA2017009I1 (en) Bruton tyrosine kinase inhibitors
BR0206984A (en) Injectable Depot Compositions and Use of These
EA200800007A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON NEUROACTIVE STEROID AND THEIR APPLICATION
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
WO2008020827A3 (en) Altered polypeptides, immunoconjugates thereof, and methods related thereto
BR0307420A (en) Compounds, pharmaceutical compositions and methods for preventing and / or treating mammalian disease
RS20060605A (en) Topical methadone compositions and methods for using the same
BR0313747A (en) Non-nucleoside Reverse Transcriptase Inhibitors
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
MX2008004734A (en) Leucine rich composition.
WO2007035612A3 (en) Polyphenol conjugates as rgd-binding compounds and methods of use
WO2006076065A3 (en) Personal care compositions
WO2006045109A3 (en) Improved orthotic appliance for carpal tunnel symdrome
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
IL175357A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
RU2004131483A (en) NATURAL HONEY-BASED COMPOSITION
TH78150A (en) Solid preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006743235

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008503532

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006743235

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11910349

Country of ref document: US